Erik De Clercq
Papers
1
Total Citations
13
H-Index
1
About
Erik De Clercq is a towering figure in antiviral research, whose pioneering work has fundamentally shaped the treatment of viral infections. His key research areas encompass the discovery and development of nucleoside analogues and antiviral agents, with a profound focus on HIV, herpes viruses, and hepatitis B. De Clercq is perhaps best known for his seminal contributions to the field, including the identification and development of tenofovir, a cornerstone drug in HIV therapy, and the discovery of the anti-herpes drug acyclovir. His impact is monumental, with his most-cited papers garnering tens of thousands of citations, reflecting decades of foundational work that has saved millions of lives. Among his many achievements, he has received numerous prestigious awards, including the Japan Prize and the Canada Gairdner International Award. His development of a cell-based ELISA for high-throughput screening of HIV-1 entry inhibitors targeting CXCR4 exemplifies his innovative approach to drug discovery, enabling rapid identification of new therapeutic candidates. De Clercq’s legacy is one of relentless dedication to translating basic virology into life-saving medicines.
Research Focus
Key Achievements
Top Papers
- 1